Five Dow Jones Stocks That Can Outperform The Market This Year

#4 Visa Inc (NYSE:V)

– Investors with Long Positions (as of December 31): 29

– Aggregate Value of Investors’ Holdings (as of December 31): $9.39 billion

Amid a 11.3% rise in its stock during the fourth quarter, investors covered by us with long positions in Visa Inc (NYSE:V) inched down by one. However, the aggregate value of their holdings increased by $818 million. Billionaire Ken Griffin‘s Citadel Investment Group was one of the notable shareholders of the payment processing giant, which reduced its stake by 50% to 3.04 million shares between October and December. For its fiscal 2016 second quarter, analysts are expecting the company to report EPS of $0.67 on revenue of $3.60 billion, whereas for the same quarter of the previous financial year it reported EPS of $0.63 on revenue of $3.40 billion. On March 14, analysts at Deutsche Bank reiterated their ‘Buy’ rating and $87 price target on the stock.

Follow Visa Inc. (NYSE:V)

#3 Pfizer Inc. (NYSE:PFE)

– Investors with Long Positions (as of December 31): 109

– Aggregate Value of Investors’ Holdings (as of December 31): $8.62 billion

Pfizer Inc. (NYSE:PFE)’s announcement in November that it would acquire Allergan plc Ordinary Shares (NYSE:AGN) for $160 billion boosted its popularity among the funds we track during the fourth quarter. In this way, the ownership of the company among investors tracked by us increased by 12 and the aggregate value of their positions jumped by $2.5 billion during that time. Billionaire Barry Rosenstein‘s JANA Partners was one of the notable shareholders that initiated a stake in the company during the October-December period and held almost 9.17 million shares of Pfizer heading into 2016. The 7% decline that shares of Pfizer Inc. (NYSE:PFE) have registered so far this year has boosted its annual dividend yield to almost 4%. On March 17, authorities in India banned the company’s highly popular cough syrup ‘Codex, which caused the stock of its Indian unit, Pfizer Limited, to lose around 7% during a single day. Though the Allergan-Pfizer merger faces a lot of regulatory hurdles currently, analysts believe that if it does get completed it will be hugely beneficial for Pfizer and its shareholders due to the synergies involved.

Follow Pfizer Inc (NYSE:PFE)